{ "instance": { "ipix_10q.htm": { "axisCustom": 0, "axisStandard": 15, "contextCount": 226, "dts": { "calculationLink": { "local": [ "ipix-20211231_cal.xml" ] }, "definitionLink": { "local": [ "ipix-20211231_def.xml" ] }, "inline": { "local": [ "ipix_10q.htm" ] }, "labelLink": { "local": [ "ipix-20211231_lab.xml" ] }, "presentationLink": { "local": [ "ipix-20211231_pre.xml" ] }, "schema": { "local": [ "ipix-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 501, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 49, "http://ipharminc.com/20211231": 68, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 122 }, "keyCustom": 155, "keyStandard": 300, "memberCustom": 51, "memberStandard": 14, "nsprefix": "ipix", "nsuri": "http://ipharminc.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://ipharminc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Patents net", "role": "http://ipharminc.com/role/PatentsNet", "shortName": "Patents net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:AccruedExpensesRelatedPartiesAndOtherTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Accrued Expenses Related Parties and Other", "role": "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOther", "shortName": "Accrued Expenses Related Parties and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:AccruedExpensesRelatedPartiesAndOtherTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Accrued Salaries and Payroll Taxes Related Parties and Other", "role": "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "shortName": "Accrued Salaries and Payroll Taxes Related Parties and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:Note7ExclusiveLicenseAgreementDisclosureTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Exclusive License Agreement", "role": "http://ipharminc.com/role/ExclusiveLicenseAgreement", "shortName": "Exclusive License Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:Note7ExclusiveLicenseAgreementDisclosureTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Operating Leases", "role": "http://ipharminc.com/role/OperatingLeases", "shortName": "Operating Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Commitments and Contingencies", "role": "http://ipharminc.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Related Party Transactions", "role": "http://ipharminc.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Convertible Note Payable Related Party", "role": "http://ipharminc.com/role/ConvertibleNotePayableRelatedParty", "shortName": "Convertible Note Payable Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Loan payable", "role": "http://ipharminc.com/role/LoanPayable", "shortName": "Loan payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:Note13EquityIncentivePlansStockBasedCompensationExerciseOfOptionsAndWarrantsOutstandingDisclosureTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstanding", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:Note13EquityIncentivePlansStockBasedCompensationExerciseOfOptionsAndWarrantsOutstandingDisclosureTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Equity Transactions", "role": "http://ipharminc.com/role/EquityTransactions", "shortName": "Equity Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Fair Value Measurement", "role": "http://ipharminc.com/role/FairValueMeasurement", "shortName": "Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Subsequent Events", "role": "http://ipharminc.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Significant Accounting Policies and Recent Accounting Pronouncements (Policies)", "role": "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies", "shortName": "Significant Accounting Policies and Recent Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Significant Accounting Policies and Recent Accounting Pronouncements (Tables)", "role": "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsTables", "shortName": "Significant Accounting Policies and Recent Accounting Pronouncements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Patents net (Tables)", "role": "http://ipharminc.com/role/PatentsNetTables", "shortName": "Patents net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ipix:AccruedExpensesRelatedPartiesAndOtherTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Accrued Expenses Related Parties and Other (Tables)", "role": "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherTables", "shortName": "Accrued Expenses Related Parties and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ipix:AccruedExpensesRelatedPartiesAndOtherTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ipix:AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:ScheduleOfAccruedSalariesAndPayrollTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Accrued Salaries and Payroll Taxes Related Parties And Other (Tables)", "role": "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherTables", "shortName": "Accrued Salaries and Payroll Taxes Related Parties And Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ipix:AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:ScheduleOfAccruedSalariesAndPayrollTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Operating Leases (Tables)", "role": "http://ipharminc.com/role/OperatingLeasesTables", "shortName": "Operating Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:ScheduleOfFairValueOfTheWarrantsAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Tables)", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingTables", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:ScheduleOfFairValueOfTheWarrantsAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:ScheduleOfChangeInFairValueOfPreferredStockTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Fair Value Measurement (Tables)", "role": "http://ipharminc.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ipix:ScheduleOfChangeInFairValueOfPreferredStockTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Liquidity (Details Narrative)", "role": "http://ipharminc.com/role/LiquidityDetailsNarrative", "shortName": "Liquidity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasicAndDiluted", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Significant Accounting Policies and Recent Accounting Pronouncements (Details)", "role": "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails", "shortName": "Significant Accounting Policies and Recent Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "lang": null, "name": "ipix:StockOptionsArisingFromConvertibleNotePayableAndAccruedInterests", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "ipix:TreasuryStockPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "ipix:TreasuryStockValues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)", "role": "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative", "shortName": "Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ipix:TreasuryStockPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "ipix:TreasuryStockValues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Patents net (Details)", "role": "http://ipharminc.com/role/PatentsNetDetails", "shortName": "Patents net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Patents net (Details Narrative)", "role": "http://ipharminc.com/role/PatentsNetDetailsNarrative", "shortName": "Patents net (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ipix:AccruedExpensesRelatedPartiesAndOtherTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ipix:AccruedConsultingFeeCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Accrued Expenses Related Parties and Other (Details)", "role": "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails", "shortName": "Accrued Expenses Related Parties and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ipix:AccruedExpensesRelatedPartiesAndOtherTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ipix:AccruedConsultingFeeCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfAccruedSalariesAndPayrollTaxesTableTextBlock", "ipix:AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Accrued Salaries and Payroll Taxes Related Parties And Other (Details)", "role": "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails", "shortName": "Accrued Salaries and Payroll Taxes Related Parties And Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfAccruedSalariesAndPayrollTaxesTableTextBlock", "ipix:AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - Exclusive License Agreement (Details Narrative)", "role": "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative", "shortName": "Exclusive License Agreement (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ipix:Note7ExclusiveLicenseAgreementDisclosureTextblock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2019-07-18_ipix_LicenseAgreementMember", "decimals": "-5", "lang": null, "name": "ipix:NonRefundablePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - Operating Leases (Details)", "role": "http://ipharminc.com/role/OperatingLeasesDetails", "shortName": "Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRentExpenseTableTextBlock", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - Operating Leases (Details 1)", "role": "http://ipharminc.com/role/OperatingLeasesDetails1", "shortName": "Operating Leases (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfMaturitiesOfTheLeaseLiabilitiesTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - Operating Leases (Details 2)", "role": "http://ipharminc.com/role/OperatingLeasesDetails2", "shortName": "Operating Leases (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfMaturitiesOfTheLeaseLiabilitiesTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2019-12-01to2019-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - Operating Leases (Details Narrative)", "role": "http://ipharminc.com/role/OperatingLeasesDetailsNarrative", "shortName": "Operating Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2019-12-01to2019-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-06-30_ipix_ClinicalStudiesMember", "decimals": "0", "first": true, "lang": null, "name": "ipix:AccruedResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-06-30_ipix_ClinicalStudiesMember", "decimals": "0", "first": true, "lang": null, "name": "ipix:AccruedResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ipix:TotalOutstandingBalanceOfPrincipalAndInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - Convertible Note Payable Related Party (Details Narrative)", "role": "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "shortName": "Convertible Note Payable Related Party (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ipix:TotalOutstandingBalanceOfPrincipalAndInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31_ipix_PaycheckProtectionProgramMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentDecreaseForgiveness", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - Loan payable (Details Narrative)", "role": "http://ipharminc.com/role/LoanPayableDetailsNarrative", "shortName": "Loan payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31_ipix_PaycheckProtectionProgramMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentDecreaseForgiveness", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfFairValueOfTheWarrantsAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2020-07-01to2020-12-31_us-gaap_StockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details)", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfFairValueOfTheWarrantsAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2020-07-01to2020-12-31_us-gaap_StockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 1)", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-06-30_us-gaap_StockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 2)", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-06-30_us-gaap_StockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2020-06-30_ipix_CommonStockAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)", "role": "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2020-07-01to2020-09-30_ipix_CommonStockAMember", "decimals": "0", "lang": null, "name": "ipix:SharesSoldToAspireCapitalUnderAgreementAtRangeShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-06-30_ipix_RestrictedStocksMember", "decimals": "0", "first": true, "lang": null, "name": "ipix:AwardsOutstandingBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 3)", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-06-30_ipix_RestrictedStocksMember", "decimals": "0", "first": true, "lang": null, "name": "ipix:AwardsOutstandingBeginningBalance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ipix:ScheduledVestingSharesOfRestrictedStock", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 4)", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ipix:ScheduledVestingSharesOfRestrictedStock", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "ipix:Note13EquityIncentivePlansStockBasedCompensationExerciseOfOptionsAndWarrantsOutstandingDisclosureTextblock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000052 - Disclosure - Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details Narrative)", "role": "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "shortName": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-10-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-02-01to2021-02-08", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000053 - Disclosure - Equity Transaction (Details Narrative)", "role": "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "shortName": "Equity Transaction (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-02-01to2021-02-08", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfChangeInFairValueOfPreferredStockTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2020-07-01to2021-06-30_ipix_SeriesBTwoPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "ipix:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000054 - Disclosure - Fair Value Measurement (Details)", "role": "http://ipharminc.com/role/FairValueMeasurementDetails", "shortName": "Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ipix:ScheduleOfChangeInFairValueOfPreferredStockTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2020-07-01to2021-06-30_ipix_SeriesBTwoPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "ipix:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2022-01-01to2022-02-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000055 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://ipharminc.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2022-01-01to2022-02-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": "0", "lang": null, "name": "ipix:AmortizationOfPatentCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Basis of Presentation and Nature of Operations", "role": "http://ipharminc.com/role/BasisOfPresentationAndNatureOfOperations", "shortName": "Basis of Presentation and Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Liquidity", "role": "http://ipharminc.com/role/Liquidity", "shortName": "Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Significant Accounting Policies and Recent Accounting Pronouncements", "role": "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncements", "shortName": "Significant Accounting Policies and Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ipix_10q.htm", "contextRef": "From2021-07-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://ipharminc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "ipix_AccruedConsultingFeeCurrent": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails": { "order": 2.0, "parentTag": "ipix_AccruedSalaryCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued research and development consulting fees" } } }, "localname": "AccruedConsultingFeeCurrent", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "ipix_AccruedDividendSeriesBFiveConvertiblesPreferredStock": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued dividend - Series B 5% convertible preferred stock" } } }, "localname": "AccruedDividendSeriesBFiveConvertiblesPreferredStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ipix_AccruedExpensesRelatedPartiesAndOtherTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "5. Accrued Expenses - Related Parties and Other" } } }, "localname": "AccruedExpensesRelatedPartiesAndOtherTextBlock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOther" ], "xbrltype": "textBlockItemType" }, "ipix_AccruedInterestRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued interest - related parties" } } }, "localname": "AccruedInterestRelatedParty", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_AccruedResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpenses", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_AccruedSalariesAndPayrollTaxesIncludingRelatedPartyAccruedSalaries": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued salaries and payroll taxes - (including related party accrued salaries of approx. $1,538,000 and $1,915,000, respectively)" } } }, "localname": "AccruedSalariesAndPayrollTaxesIncludingRelatedPartyAccruedSalaries", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ipix_AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "6. Accrued Salaries and Payroll Taxes - Related Parties and Other" } } }, "localname": "AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOther" ], "xbrltype": "textBlockItemType" }, "ipix_AccruedSalaryCurrent": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total]", "totalLabel": "Total" } } }, "localname": "AccruedSalaryCurrent", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "ipix_AdditionalCancelledShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional cancelled shares" } } }, "localname": "AdditionalCancelledShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_AdditionalPaymentsPayablesUponAchievementOfCertainMilestonesUnderAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Additional payments payable upon achievement of certain milestones under agreement by related party" } } }, "localname": "AdditionalPaymentsPayablesUponAchievementOfCertainMilestonesUnderAgreement", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_AdditionalWarrantPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional warrant purchase" } } }, "localname": "AdditionalWarrantPurchase", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_AggregateIntrinsicValueBeginning": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value beginning" } } }, "localname": "AggregateIntrinsicValueBeginning", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "monetaryItemType" }, "ipix_AggregateIntrinsicValueEnding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value ending" } } }, "localname": "AggregateIntrinsicValueEnding", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "monetaryItemType" }, "ipix_AggregateIntrinsicValueExercisable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value Exercisable" } } }, "localname": "AggregateIntrinsicValueExercisable", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "monetaryItemType" }, "ipix_AggregateIntrinsicValueUnvestedStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value unvested stock options" } } }, "localname": "AggregateIntrinsicValueUnvestedStockOptions", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "monetaryItemType" }, "ipix_AggregatePurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate purchase", "verboseLabel": "Aggregate Purchase" } } }, "localname": "AggregatePurchase", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_AmortizationOfPatentCosts": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization of patent costs" } } }, "localname": "AmortizationOfPatentCosts", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_AmortizationPeriodOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amortization period of restricted stock" } } }, "localname": "AmortizationPeriodOfRestrictedStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "durationItemType" }, "ipix_AnnualLimitDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual limit description" } } }, "localname": "AnnualLimitDescription", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "stringItemType" }, "ipix_AspireCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aspire Capital [Member]" } } }, "localname": "AspireCapitalMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_AvailableBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Available balance" } } }, "localname": "AvailableBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_AvailableBalanceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Available balance, Amount" } } }, "localname": "AvailableBalanceAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_AwardsOutstandingBeginningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Awards outstanding, Beginning balance]", "periodStartLabel": "Awards outstanding, Beginning balance" } } }, "localname": "AwardsOutstandingBeginningBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "sharesItemType" }, "ipix_BeginningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Beginning Balance" } } }, "localname": "BeginningBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "ipix_BeneficiallyOwnInExcessCoversion": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Beneficially own in excess coversion" } } }, "localname": "BeneficiallyOwnInExcessCoversion", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "percentItemType" }, "ipix_CancellationOfClassASharesToSatisfyThePurchaseOfCommonStockClassBAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cancellation of 6,980,583 Class A shares to satisfy the purchase of 13,072,730 shares of Common Stock Class B amount" } } }, "localname": "CancellationOfClassASharesToSatisfyThePurchaseOfCommonStockClassBAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_CancellationOfClassASharesToSatisfyThePurchaseOfCommonStockClassBShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation of 6,980,583 Class A shares to satisfy the purchase of 13,072,730 shares of Common Stock Class B shares" } } }, "localname": "CancellationOfClassASharesToSatisfyThePurchaseOfCommonStockClassBShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_CancellationOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cancellation of debt" } } }, "localname": "CancellationOfDebt", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_CancellationOfDebtForThePurchaseOfCommonStockClassBWereWithheldForTaxPurposesAsTreasuryAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cancellation of debt for the purchase of 909,090 shares of Common Stock Class B & 181,096 shares were withheld for tax purposes as Treasury shares amount" } } }, "localname": "CancellationOfDebtForThePurchaseOfCommonStockClassBWereWithheldForTaxPurposesAsTreasuryAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_CancellationOfDebtForThePurchaseOfCommonStockClassBWereWithheldForTaxPurposesAsTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation of debt for the purchase of 909,090 shares of Common Stock Class B & 181,096 shares were withheld for tax purposes as Treasury shares shares" } } }, "localname": "CancellationOfDebtForThePurchaseOfCommonStockClassBWereWithheldForTaxPurposesAsTreasuryShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_CancellationOfShareholderDebtForThePurchaseOf31MSharesOfCommonStockClassBShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cancellation of shareholder debt for the purchase of 3.1M shares of Common Stock Class B shares" } } }, "localname": "CancellationOfShareholderDebtForThePurchaseOf31MSharesOfCommonStockClassBShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_CancellationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation shares" } } }, "localname": "CancellationShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_CashPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash payment percentage" } } }, "localname": "CashPaymentPercentage", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "percentItemType" }, "ipix_ChangeInFairValueOfSeriesBTwoPreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in fair value of Series B-2 preferred stock" } } }, "localname": "ChangeInFairValueOfSeriesBTwoPreferredStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "ipix_ClassACommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Common Stock [Member]", "verboseLabel": "Class A Common Stock [Member]" } } }, "localname": "ClassACommonStockMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_ClassBCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Common Stock [Member]" } } }, "localname": "ClassBCommonStockMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_ClinicalActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Clinical activities" } } }, "localname": "ClinicalActivities", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_ClinicalStudiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Clinical Studies [Member]" } } }, "localname": "ClinicalStudiesMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_ClosingBidPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Closing bid price" } } }, "localname": "ClosingBidPrice", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_ClosingBidPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Closing bid price per share" } } }, "localname": "ClosingBidPricePerShare", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipix_ClosingStockPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Closing stock price" } } }, "localname": "ClosingStockPrice", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_ClosingStockPricePerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Closing stock price, per shares" } } }, "localname": "ClosingStockPricePerShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipix_CommonStockAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock A" } } }, "localname": "CommonStockAMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "ipix_CommonStockBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock B" } } }, "localname": "CommonStockBMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "ipix_CommonStockHeldSatisfyExercisePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock held satisfy exercise price" } } }, "localname": "CommonStockHeldSatisfyExercisePrice", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_CommonStockShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and", "label": "[Common stock, shares issued]", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockShareIssued", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_CommonStockSharesOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "[Common Stock, shares outstanding]", "verboseLabel": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstandingShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_CommonStocksSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Common stock, Shares issued" } } }, "localname": "CommonStocksSharesIssued", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_CommonStocksSharesPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares issued upon extinguishment of debt", "verboseLabel": "Common stock shares issued upon extinguishment of debt" } } }, "localname": "CommonStocksSharesPurchase", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_ConversionOfPreferredStocksIntoCommonStocksAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of 1,183 preferred stocks into 9,346,303 common stocks amount" } } }, "localname": "ConversionOfPreferredStocksIntoCommonStocksAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_ConversionOfPreferredStocksIntoCommonStocksShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of 1,183 preferred stocks into 9,346,303 common stocks shares" } } }, "localname": "ConversionOfPreferredStocksIntoCommonStocksShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_ConversionOfSeriesBConvertiblePreferredStockToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Series B Convertible Preferred stock to Common stock" } } }, "localname": "ConversionOfSeriesBConvertiblePreferredStockToCommonStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_ConversionOfSeriesBConvertiblePreferredStockToCommonStockReversed": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of Series B Convertible Preferred stock to Common stock, reversed" } } }, "localname": "ConversionOfSeriesBConvertiblePreferredStockToCommonStockReversed", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_ConversionOfSeriesBTwoPreferredStockToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of Series B-2 preferred stock to common stock" } } }, "localname": "ConversionOfSeriesBTwoPreferredStockToCommonStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "ipix_ConversionOfSharesOfPreferredStockIntoSharesOfCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of shares of preferred stock into shares of common stock amount" } } }, "localname": "ConversionOfSharesOfPreferredStockIntoSharesOfCommonStockAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_ConversionOfSharesOfPreferredStockIntoSharesOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of shares of preferred stock into shares of common stock shares" } } }, "localname": "ConversionOfSharesOfPreferredStockIntoSharesOfCommonStockShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_ConversionOfwentyTwentySeriesB5ConvertiblePreferredStockcommonstockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion of 2020 Series B-2 5% convertible preferred stock to common stock [Member]" } } }, "localname": "ConversionOfwentyTwentySeriesB5ConvertiblePreferredStockcommonstockMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_ConvertiblePreferredStockExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails": { "order": 5.0, "parentTag": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" }, "ipix_ConvertiblePreferredStockExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, exercise" } } }, "localname": "ConvertiblePreferredStockExercise", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_ConvertiblePreferredStockIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible preferred stock into common stock" } } }, "localname": "ConvertiblePreferredStockIntoCommonStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_ConvertiblePreferredStockLiabilityAt1080StatedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible preferred stock liability stated value" } } }, "localname": "ConvertiblePreferredStockLiabilityAt1080StatedValue", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "ipix_ConvertiblePreferredStockLiabilitySharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible preferred stock liability shares issued" } } }, "localname": "ConvertiblePreferredStockLiabilitySharesIssued", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "ipix_ConvertiblePreferredStockLiabilitySharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible preferred stock liability shares outstanding" } } }, "localname": "ConvertiblePreferredStockLiabilitySharesOutstanding", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "ipix_ConvertiblePreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, shares" } } }, "localname": "ConvertiblePreferredStockShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_CumulativeCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cumulative cost" } } }, "localname": "CumulativeCost", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_CurrentLiabilitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Total Current Liabilities]", "verboseLabel": "Total Current Liabilities" } } }, "localname": "CurrentLiabilitiesAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_DebtCancellation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amount of debt extinguished", "verboseLabel": "Amount of debt extinguished" } } }, "localname": "DebtCancellation", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_DecemberTwentyNineTwoThousandTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 29, 2010 [Member]" } } }, "localname": "DecemberTwentyNineTwoThousandTenMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_DrKrishnaMenonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dr Krishna Menon [Member]" } } }, "localname": "DrKrishnaMenonMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_EhrlichMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Mr. Ehrlich [Member]]", "verboseLabel": "Mr. Ehrlich [Member]" } } }, "localname": "EhrlichMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_EhrlichPromissoryNoteCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ehrlich Promissory Note C [Member]" } } }, "localname": "EhrlichPromissoryNoteCMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_EndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Ending Balance" } } }, "localname": "EndingBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "ipix_EndingBalanceOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ending balance, outstanding" } } }, "localname": "EndingBalanceOutstanding", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "sharesItemType" }, "ipix_Exercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable" } } }, "localname": "Exercisable", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "sharesItemType" }, "ipix_ExercisablePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable period" } } }, "localname": "ExercisablePeriod", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "durationItemType" }, "ipix_ExerciseOfSeriesOneAndTwoWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Exercise of Series 1 and 2 warrants" } } }, "localname": "ExerciseOfSeriesOneAndTwoWarrants", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "ipix_ExerciseOfwentyTwentySeriesB5ConvertiblePreferredStockWarrantsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise of 2020 Series B 5% Convertible Preferred Stock Warrants 1 [Member]" } } }, "localname": "ExerciseOfwentyTwentySeriesB5ConvertiblePreferredStockWarrantsOneMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_ExerciseOfwentyTwentySeriesConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise of 2020 Series B 2.5% Convertible Preferred Stock Warrant [Member]" } } }, "localname": "ExerciseOfwentyTwentySeriesConvertiblePreferredStockWarrantsMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_ExercisePriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price description" } } }, "localname": "ExercisePriceDescription", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ipix_FebruaryTenTwentyTwentyOneContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February 10, 2021 [Member]" } } }, "localname": "FebruaryTenTwentyTwentyOneContractsMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_FebruaryTwentyThreeTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February 23, 2020 [Member]" } } }, "localname": "FebruaryTwentyThreeTwoThousandTwentyMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_Forfeitedexpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or tha", "label": "Forfeited/expired" } } }, "localname": "Forfeitedexpired", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "sharesItemType" }, "ipix_FutureBudgetExpenditures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Future budget expenditures" } } }, "localname": "FutureBudgetExpenditures", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_GrossProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gross proceeds" } } }, "localname": "GrossProceeds", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_IncreaseDecreaseOperatingLeasesLiability": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating lease liability" } } }, "localname": "IncreaseDecreaseOperatingLeasesLiability", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_IntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IntangibleAssets [Member]" } } }, "localname": "IntangibleAssetsMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_IssuanceOfSharesForTaxPurposesAsTreasuryAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of shares for tax purposes as Treasury Shares amount" } } }, "localname": "IssuanceOfSharesForTaxPurposesAsTreasuryAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_IssuanceOfSharesForTaxPurposesAsTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of shares for tax purposes as Treasury Shares shares" } } }, "localname": "IssuanceOfSharesForTaxPurposesAsTreasuryShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_IssuanceOfSharesToEmployeeSharesWereWithheldForTaxPurposesAsTreasurySharesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of 58,394 shares to employee & 21,606 shares were withheld for tax purposes as Treasury shares amount" } } }, "localname": "IssuanceOfSharesToEmployeeSharesWereWithheldForTaxPurposesAsTreasurySharesAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_IssuanceOfSharesToEmployeeSharesWereWithheldForTaxPurposesAsTreasurySharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of 58,394 shares to employee & 21,606 shares were withheld for tax purposes as Treasury shares shares" } } }, "localname": "IssuanceOfSharesToEmployeeSharesWereWithheldForTaxPurposesAsTreasurySharesShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_IssuanceOneOfSharesForTaxPurposesAsTreasuryAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance one of shares for tax purposes as Treasury Shares amount" } } }, "localname": "IssuanceOneOfSharesForTaxPurposesAsTreasuryAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_IssuanceOneOfSharesForTaxPurposesAsTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance one of shares for tax purposes as Treasury Shares shares" } } }, "localname": "IssuanceOneOfSharesForTaxPurposesAsTreasuryShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_JulyOneTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 1, 2021 [Member]" } } }, "localname": "JulyOneTwoThousandTwentyOneMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_JulyThirtyTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 30, 2020 [Member]" } } }, "localname": "JulyThirtyTwoThousandTwentyMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_JulyTwentythreeTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 23, 2020 [Member]" } } }, "localname": "JulyTwentythreeTwoThousandTwentyMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_JuneThirtyTwoThousandSixteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "June 30, 2016 [Member]" } } }, "localname": "JuneThirtyTwoThousandSixteenMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_MayEighteenTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May 18, 2020 [Member]" } } }, "localname": "MayEighteenTwoThousandTwentyMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_MrEhrlichMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr. Ehrlich [Member]", "verboseLabel": "Mr Ehrlich [Member]" } } }, "localname": "MrEhrlichMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_MsJaneHarnessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ms Jane Harness [Member]" } } }, "localname": "MsJaneHarnessMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_NetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net loss]", "verboseLabel": "Net loss" } } }, "localname": "NetLoss", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_NonRefundablePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non-refundable payment" } } }, "localname": "NonRefundablePayments", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_Note13EquityIncentivePlansStockBasedCompensationExerciseOfOptionsAndWarrantsOutstandingDisclosureTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "13. Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding" } } }, "localname": "Note13EquityIncentivePlansStockBasedCompensationExerciseOfOptionsAndWarrantsOutstandingDisclosureTextblock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstanding" ], "xbrltype": "textBlockItemType" }, "ipix_Note7ExclusiveLicenseAgreementDisclosureTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "7. Exclusive License Agreement" } } }, "localname": "Note7ExclusiveLicenseAgreementDisclosureTextblock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ExclusiveLicenseAgreement" ], "xbrltype": "textBlockItemType" }, "ipix_OctoberTwoTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2, 2020 [Member]" } } }, "localname": "OctoberTwoTwoThousandTwentyMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_OfferingCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Offering cost" } } }, "localname": "OfferingCost", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_OnOctoberTenTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "On October Ten Two Thousand Twenty One [Member]" } } }, "localname": "OnOctoberTenTwoThousandTwentyOneMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_OnSeptember12019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[On September 1, 2019 [Member]]", "verboseLabel": "On September 1, 2019 [Member]" } } }, "localname": "OnSeptember12019Member", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_OnSeptemberElevenTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "On September 11, 2020 [Member]" } } }, "localname": "OnSeptemberElevenTwoThousandTwentyMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_OnSeptemberOneTwoThousandEighteenteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "On September 1, 2018 [Member]" } } }, "localname": "OnSeptemberOneTwoThousandEighteenteenMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_OnSeptemberOneTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "On September 1, 2019 [Member]" } } }, "localname": "OnSeptemberOneTwoThousandNineteenMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_OneConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Consultant [Member]" } } }, "localname": "OneConsultantMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_OperatingLeaseWeightedAverageRemainingLeaseTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerms", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "ipix_OptionsToPurchaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options to purchase shares" } } }, "localname": "OptionsToPurchaseShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_OriginatedInTwoThousandTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Originated In 2010 [Member]" } } }, "localname": "OriginatedInTwoThousandTenMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_PatentCosts": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Patent costs" } } }, "localname": "PatentCosts", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_PatentsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents Three [Member]" } } }, "localname": "PatentsThreeMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails" ], "xbrltype": "domainItemType" }, "ipix_PatentsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents Two [Member]" } } }, "localname": "PatentsTwoMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails" ], "xbrltype": "domainItemType" }, "ipix_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_PaymentDueFollowingCommencementsOfFirstPhaseThreeClinicalTrialOfBrilacidin": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment due following commencement of first phase III clinical trial of Brilacidin" } } }, "localname": "PaymentDueFollowingCommencementsOfFirstPhaseThreeClinicalTrialOfBrilacidin", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_PaymentDueUponFilingOfAMarketingApprovalApplication": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment due upon filing of a marketing approval application" } } }, "localname": "PaymentDueUponFilingOfAMarketingApprovalApplication", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_PerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Per share" } } }, "localname": "PerShare", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ipix_PercentageClosingBidPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of closing bid price" } } }, "localname": "PercentageClosingBidPrice", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "percentItemType" }, "ipix_PreferredStockAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Preferred stock amount" } } }, "localname": "PreferredStockAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_PreferredStockLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred stock liability" } } }, "localname": "PreferredStockLiability", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_PreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred stock shares" } } }, "localname": "PreferredStockShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_PrincipalBalancesOfDemandNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Principal balance of demand notes" } } }, "localname": "PrincipalBalancesOfDemandNote", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_ProvisionForIncomeTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Provision for income taxes" } } }, "localname": "ProvisionForIncomeTaxes", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_PurchaseOfSharesOfCommonStockClassBToOfficerSharesWereWithheldForTaxPurposesAsTreasurySharesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchase of 2,200,000 shares of Common Stock Class B to Officer & 412,238 shares were withheld for tax purposes as Treasury shares amount" } } }, "localname": "PurchaseOfSharesOfCommonStockClassBToOfficerSharesWereWithheldForTaxPurposesAsTreasurySharesAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_PurchaseOfSharesOfCommonStockClassBToOfficersharesWereWithheldForTaxPurposesAsTreasurySharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase of 2,200,000 shares of Common Stock Class B to Officer & 412,238 shares were withheld for tax purposes as Treasury shares shares" } } }, "localname": "PurchaseOfSharesOfCommonStockClassBToOfficersharesWereWithheldForTaxPurposesAsTreasurySharesShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_RelatedPartyAccruedSalaries": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Related party accrued salaries" } } }, "localname": "RelatedPartyAccruedSalaries", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "ipix_RelatedPartyExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Related party expenses" } } }, "localname": "RelatedPartyExpenses", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "ipix_RestrictedStockAwardsOfCommonStockIssuedToEmployeeForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Restricted stock awards of common stock issued to employee for services at $0.132 to $0.398" } } }, "localname": "RestrictedStockAwardsOfCommonStockIssuedToEmployeeForServices", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_RestrictedStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStocksMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "domainItemType" }, "ipix_ReversedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Reversed amount" } } }, "localname": "ReversedAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_ScheduleOfAccruedSalariesAndPayrollTaxesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of accrued salaries and payroll taxes" } } }, "localname": "ScheduleOfAccruedSalariesAndPayrollTaxesTableTextBlock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherTables" ], "xbrltype": "textBlockItemType" }, "ipix_ScheduleOfChangeInFairValueOfPreferredStockTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Change in fair value of preferred stock" } } }, "localname": "ScheduleOfChangeInFairValueOfPreferredStockTableTextblock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "ipix_ScheduleOfFairValueOfTheWarrantsAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value of the warrants assumptions" } } }, "localname": "ScheduleOfFairValueOfTheWarrantsAssumptionsTableTextBlock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingTables" ], "xbrltype": "textBlockItemType" }, "ipix_ScheduleOfMaturitiesOfTheLeaseLiabilitiesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of maturities of the lease liabilities" } } }, "localname": "ScheduleOfMaturitiesOfTheLeaseLiabilitiesTableTextblock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/OperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "ipix_ScheduledVestingSharesOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scheduled vesting" } } }, "localname": "ScheduledVestingSharesOfRestrictedStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4" ], "xbrltype": "sharesItemType" }, "ipix_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_SeriesBConvertiblePreferredStockwarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock warrants [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockwarrantsMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_SeriesBFiveConvertiblePreferredStockLiability": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series B 5% convertible preferred stock liability at $1,080 stated value; 1,500 and 0 shares issued and outstanding at December 31, 2021 and June 30, 2021, respectively" } } }, "localname": "SeriesBFiveConvertiblePreferredStockLiability", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ipix_SeriesBTwoPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B-2 Preferred Stock [Member]" } } }, "localname": "SeriesBTwoPreferredStockMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ipix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "sharesItemType" }, "ipix_SharesIssuedAsCommitmentFeeAtNetAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued as commitment fee of $1,438,000 on 7/31/2020 at $0.23, net of amortization of offering costs of $120,000 amount" } } }, "localname": "SharesIssuedAsCommitmentFeeAtNetAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_SharesIssuedAsCommitmentFeeAtNetShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued as commitment fee of $1,438,000 on 7/31/2020 at $0.23, net of amortization of offering costs of $120,000 shares" } } }, "localname": "SharesIssuedAsCommitmentFeeAtNetShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_SharesIssuedAsDeferredOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued as deferred offering costs" } } }, "localname": "SharesIssuedAsDeferredOfferingCosts", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_SharesIssuedToEmployeeForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued to employee for services at $0.132 to $0.398" } } }, "localname": "SharesIssuedToEmployeeForServices", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_SharesOfCommonStockIssuedForExerciseOfOptionsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares of common stock issued for exercise of options amount" } } }, "localname": "SharesOfCommonStockIssuedForExerciseOfOptionsAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_SharesOfCommonStockIssuedForExerciseOfOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares of common stock issued for exercise of options shares" } } }, "localname": "SharesOfCommonStockIssuedForExerciseOfOptionsShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_SharesSoldToAspireCapitalUnderAgreementAtRangeAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares sold to Aspire Capital under 2020 Agreement at $0.20 - $0.22 range amount" } } }, "localname": "SharesSoldToAspireCapitalUnderAgreementAtRangeAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_SharesSoldToAspireCapitalUnderAgreementAtRangeShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares sold to Aspire Capital under 2020 Agreement at $0.20 - $0.22 range shares" } } }, "localname": "SharesSoldToAspireCapitalUnderAgreementAtRangeShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_SharesSoldToAspireUnderAgreementAtRangeAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares sold to Aspire under 2020 Agreement at $0.20 - $0.22 range amount" } } }, "localname": "SharesSoldToAspireUnderAgreementAtRangeAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_SharesSoldToAspireUnderAgreementAtRangeShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares sold to Aspire under 2020 Agreement at $0.20 - $0.22 range shares" } } }, "localname": "SharesSoldToAspireUnderAgreementAtRangeShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_SharesWereWithheldForTaxPurposesAsTreasurySharesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares were withheld for tax purposes as Treasury Shares amount" } } }, "localname": "SharesWereWithheldForTaxPurposesAsTreasurySharesAmount", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_SharesWereWithheldForTaxPurposesAsTreasurySharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares were withheld for tax purposes as Treasury Shares shares" } } }, "localname": "SharesWereWithheldForTaxPurposesAsTreasurySharesShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ipix_StockIssuedDuringPeriodSharesStockOptionExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionExercised", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "sharesItemType" }, "ipix_StockOptionVestedDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock option vested or to be vested, description" } } }, "localname": "StockOptionVestedDescription", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "stringItemType" }, "ipix_StockOptionsArisingFromConvertibleNotePayableAndAccruedInterests": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails": { "order": 3.0, "parentTag": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Stock options arising from convertible note payable and accrued interest" } } }, "localname": "StockOptionsArisingFromConvertibleNotePayableAndAccruedInterests", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" }, "ipix_StockOptionsIssuedToConsultantForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock options issued to consultant for services" } } }, "localname": "StockOptionsIssuedToConsultantForServices", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_StockOptionsIssuedToConsultantsForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock options issued to consultants for services" } } }, "localname": "StockOptionsIssuedToConsultantsForServices", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_StockOptionsIssuedToDirectorForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock options issued to director for services at $0.24" } } }, "localname": "StockOptionsIssuedToDirectorForServices", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_StockOptionsIssuedToEmployeeForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock options issued to employee for services at $0.132 to $0.398" } } }, "localname": "StockOptionsIssuedToEmployeeForServices", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_StockOptionsToPurchaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock options to purchase shares" } } }, "localname": "StockOptionsToPurchaseShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_ToRecordBeneficialConversionFeatureAssociatedWithTheIssuanceOfSeriesB2PreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "To record beneficial conversion feature associated with the issuance of the 3,053 shares of Series B-2 preferred stock" } } }, "localname": "ToRecordBeneficialConversionFeatureAssociatedWithTheIssuanceOfSeriesB2PreferredStock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_ToRecordIssuanceCostsSeries12Warrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "To record issuance costs Series 1 & 2 Warrants" } } }, "localname": "ToRecordIssuanceCostsSeries12Warrants", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_ToRecordSeriesBDiscountWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "To record Series B Discount Warrants" } } }, "localname": "ToRecordSeriesBDiscountWarrants", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ipix_TotalOutstandingBalanceOfPrincipalAndInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total outstanding balance of principal and interest" } } }, "localname": "TotalOutstandingBalanceOfPrincipalAndInterest", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_TreasuryStockPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Treasury Stock]", "verboseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockPolicyTextBlock", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "ipix_TreasuryStockShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "[Treasury Stock Shares]", "verboseLabel": "Treasury Stock Shares" } } }, "localname": "TreasuryStockShare", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_TreasuryStockValues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, value" } } }, "localname": "TreasuryStockValues", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_TwentyThousandTwentyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2020 Agreement [Member]" } } }, "localname": "TwentyThousandTwentyAgreementMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwentyTwentySeriesB5ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2020 Series B 5% Convertible Preferred Stock [Member]" } } }, "localname": "TwentyTwentySeriesB5ConvertiblePreferredStockMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwentyTwentySeriesB5ConvertiblePreferredStockOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2020 Series B 5% Convertible Preferred Stock 1 [Member]" } } }, "localname": "TwentyTwentySeriesB5ConvertiblePreferredStockOneMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwentyTwentySeriesB5ConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2020 Series B 5% Convertible Preferred Stock Warrant [Member]" } } }, "localname": "TwentyTwentySeriesB5ConvertiblePreferredStockWarrantsMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwentyTwentySeriesB5ConvertiblePreferredStockWarrantsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2020 Series B 5% Convertible Preferred Stock Warrant 1 [Member]" } } }, "localname": "TwentyTwentySeriesB5ConvertiblePreferredStockWarrantsOneMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwoConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Consultant [Member]" } } }, "localname": "TwoConsultantMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwoPreferredStockholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Preferred Stockholders [Member]" } } }, "localname": "TwoPreferredStockholdersMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwoThaousandSixteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[2016 Equity Incentive Plan [Member]]", "verboseLabel": "2016 Equity Incentive Plan [Member]" } } }, "localname": "TwoThaousandSixteenEquityIncentivePlanMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_TwoThousandSixteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2016 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandSixteenEquityIncentivePlanMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "ipix_UnvestedStockOption": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unvested stock options" } } }, "localname": "UnvestedStockOption", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "sharesItemType" }, "ipix_VestedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested shares" } } }, "localname": "VestedShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_WarrantPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant purchase" } } }, "localname": "WarrantPurchase", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_WarrantShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant shares" } } }, "localname": "WarrantShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_WeightedAverageEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average, ending balance" } } }, "localname": "WeightedAverageEndingBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageExercisePriceBeginningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, beginning balance" } } }, "localname": "WeightedAverageExercisePriceBeginningBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageExercisePriceEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, ending balance" } } }, "localname": "WeightedAverageExercisePriceEndingBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageExercisePriceExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercisable" } } }, "localname": "WeightedAverageExercisePriceExercisable", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageExercisePriceExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised" } } }, "localname": "WeightedAverageExercisePriceExercised", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageExercisePriceForfeitedExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, forfeited/expired" } } }, "localname": "WeightedAverageExercisePriceForfeitedExpired", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageExercisePriceGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted" } } }, "localname": "WeightedAverageExercisePriceGranted", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageExercisePriceUnvestedStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, unvested stock options" } } }, "localname": "WeightedAverageExercisePriceUnvestedStockOptions", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageRemainingContractualLifeEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, ending balance" } } }, "localname": "WeightedAverageRemainingContractualLifeEndingBalance", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "durationItemType" }, "ipix_WeightedAverageRemainingContractualLifeExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, Exercisable" } } }, "localname": "WeightedAverageRemainingContractualLifeExercisable", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "durationItemType" }, "ipix_WeightedAverageRemainingContractualLifeGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, granted" } } }, "localname": "WeightedAverageRemainingContractualLifeGranted", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "durationItemType" }, "ipix_WeightedAverageRemainingContractualLifeUnvestedStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, Unvested stock options" } } }, "localname": "WeightedAverageRemainingContractualLifeUnvestedStockOptions", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "durationItemType" }, "ipix_WeightedAverageTotalSharesForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average, total shares forfeited" } } }, "localname": "WeightedAverageTotalSharesForfeited", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageTotalSharesGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average, total shares granted" } } }, "localname": "WeightedAverageTotalSharesGranted", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "perShareItemType" }, "ipix_WeightedAverageTotalSharesVested": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average, total shares vested" } } }, "localname": "WeightedAverageTotalSharesVested", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "perShareItemType" }, "ipix_WithheldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Withheld shares" } } }, "localname": "WithheldShares", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ipix_WithholdingTaxRelatedParties": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails": { "order": 4.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Withholding tax - payroll" } } }, "localname": "WithholdingTaxRelatedParties", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "ipix_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ipix_YearEndingJuneThirtyTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Year Ending June 30, 2024 [Member]" } } }, "localname": "YearEndingJuneThirtyTwoThousandTwentyFourMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4" ], "xbrltype": "domainItemType" }, "ipix_YearEndingJuneThirtyTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Year Ending June 30, 2023 [Member]" } } }, "localname": "YearEndingJuneThirtyTwoThousandTwentyThreeMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4" ], "xbrltype": "domainItemType" }, "ipix_ZorikSpektorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Zorik Spektor [Member]" } } }, "localname": "ZorikSpektorMember", "nsuri": "http://ipharminc.com/20211231", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r185", "r209", "r231", "r232", "r329", "r330", "r331", "r332", "r333", "r334", "r353", "r388", "r389", "r405", "r406" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r185", "r209", "r231", "r232", "r329", "r330", "r331", "r332", "r333", "r334", "r353", "r388", "r389", "r405", "r406" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r185", "r209", "r228", "r231", "r232", "r329", "r330", "r331", "r332", "r333", "r334", "r353", "r388", "r389", "r405", "r406" ], "lang": { "en-us": { "role": { "label": "Range Axis" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r185", "r209", "r228", "r231", "r232", "r329", "r330", "r331", "r332", "r333", "r334", "r353", "r388", "r389", "r405", "r406" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r88", "r89", "r90", "r91", "r92", "r93", "r104", "r143", "r144", "r254", "r259", "r273", "r274", "r275", "r276", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r419", "r420" ], "lang": { "en-us": { "role": { "label": "Restatement Axis" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r88", "r89", "r90", "r91", "r92", "r93", "r104", "r143", "r144", "r254", "r259", "r273", "r274", "r275", "r276", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r419", "r420" ], "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r134", "r313" ], "lang": { "en-us": { "role": { "label": "Title Of Individual Axis" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies and Recent Accounting Pronouncements" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25", "r319" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable - (including related party payables of approx. $1,511,000 and $1,511,000, respectively)" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r374", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableInterestBearingInterestRate": { "auth_ref": [ "r289", "r290", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.", "label": "Interest rate" } } }, "localname": "AccountsPayableInterestBearingInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses - (including related party accruals of approx. $29,000 and $8,000, respectively)" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r374", "r384" ], "calculation": { "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails": { "order": 4.0, "parentTag": "ipix_AccruedSalaryCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued interest (Note 11) - related parties" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r9", "r28" ], "calculation": { "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails": { "order": 3.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll taxes - related parties" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent": { "auth_ref": [ "r374", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.", "label": "Accrued salaries and payroll taxes" } } }, "localname": "AccruedPayrollTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRentCurrent": { "auth_ref": [ "r8", "r9", "r28" ], "calculation": { "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails": { "order": 3.0, "parentTag": "ipix_AccruedSalaryCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued rent (Note 10) - related parties" } } }, "localname": "AccruedRentCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r254", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r78", "r79", "r80", "r251", "r252", "r253", "r274" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional PaidIn Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r60", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortized expenses" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Reduction in warrant additional paid-in capital" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r183", "r222", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Warrants amount" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AirlineRelatedInventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents net" } } }, "localname": "AirlineRelatedInventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r233", "r248", "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r60", "r155", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "[Amortization of Intangible Assets]", "verboseLabel": "Amortization of patent costs" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r102" ], "calculation": { "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "[Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount]", "totalLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r74", "r120", "r123", "r129", "r141", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r262", "r264", "r278", "r317", "r319", "r371", "r380" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r35", "r74", "r141", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r262", "r264", "r278", "r317", "r319" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r234", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Transaction (Details Narrative)" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r4", "r77", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "1. Basis of Presentation and Nature of Operations" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/BasisOfPresentationAndNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r23", "r319", "r400", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "[Cash]", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r23", "r62" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "CASH, END OF PERIOD", "periodStartLabel": "CASH, BEGINNING OF PERIOD" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r54", "r280" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r71", "r74", "r95", "r96", "r97", "r99", "r101", "r106", "r107", "r108", "r141", "r172", "r176", "r177", "r178", "r181", "r182", "r207", "r208", "r211", "r215", "r278", "r411" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/FairValueMeasurementDetails", "http://ipharminc.com/role/LiquidityDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative", "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Stock option exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r167", "r168", "r169", "r170", "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "9. Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common stock available for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r78", "r79", "r274" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common stock price per share", "verboseLabel": "Common stock price per share" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, shares issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r222" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock", "verboseLabel": "Common stock value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual commitments" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock options, vested percentage description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock conversion, number of shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock shares issued upon conversion of preferred stock", "verboseLabel": "Stock conversion, number of shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r207", "r208", "r211" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r64", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion amount limits" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses Related Parties and Other" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r70", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r198", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "11. Convertible Note Payable - Related Party" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedParty" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Loan forgivness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Deferred offering costs" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r33", "r154" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "[Deferred Offering Costs]", "verboseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "June 30, 2027 and Thereafter" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "June 30, 2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "June 30, 2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "June 30, 2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "June 30, 2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r36", "r266", "r267", "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument Risk Axis" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exclusive License Agreement (Details Narrative)" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding (Tables)" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r224", "r378" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Accrued dividend" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r11", "r12", "r372", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Accrued dividends" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted loss per share attributable to common stockholders", "verboseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "[Employee-related Liabilities, Current]", "totalLabel": "Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r374", "r384" ], "calculation": { "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails": { "order": 2.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued salaries - related parties" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/AccruedSalariesAndPayrollTaxesRelatedPartiesAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r39", "r40", "r41", "r78", "r79", "r80", "r82", "r89", "r92", "r105", "r142", "r222", "r224", "r251", "r252", "r253", "r258", "r259", "r274", "r281", "r282", "r283", "r284", "r285", "r286", "r390", "r391", "r392", "r420" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Incentive Plans StockBased Compensation Exercise of Options and Warrants Outstanding" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan payable" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r60", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Warrant discounts" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "15. Fair value measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "auth_ref": [ "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.", "label": "Change in fair value" } } }, "localname": "FairValueOptionChangesInFairValueGainLoss1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r197", "r220", "r272", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r411", "r412", "r413", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument Axis" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Useful life", "verboseLabel": "Future amortization period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r160" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "June 30, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r156", "r158", "r160", "r163", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class Axis" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r160", "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patent costs - gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r156", "r159" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r160", "r356" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patent costs - net", "verboseLabel": "Patent costs - net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/PatentsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated remaining useful lives of the assets" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r60", "r202", "r203" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on forgiveness of loans payable" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r75", "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r57", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for tax" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r59" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued officers' salaries and payroll taxes" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r59" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Prepaid expenses and security deposits" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r157", "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite Lived Intangible Assets By Major Class Axis" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r157", "r162" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "4. Patents, net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents net (Tables)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r42", "r119", "r288", "r292", "r376" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense-preferred stock" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r49", "r194", "r199", "r200", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "[Interest Expense, Debt]", "negatedLabel": "Interest expense - debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "[Interest Expense, Related Party]", "negatedLabel": "Interest expense - preferred stock liability" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r53", "r56", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Officers' payroll and payroll tax expenses" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r305", "r307" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "[Lease, Cost]", "totalLabel": "Total operating cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases", "verboseLabel": "Operating leases" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r306" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "[Lessee, Operating Lease, Liability, to be Paid]", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r306" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails2": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r306" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails2": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024 (remaining 3 months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r306" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less: Imputed interest/present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r74", "r124", "r141", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r263", "r264", "r265", "r278", "r317", "r318" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r74", "r141", "r278", "r319", "r373", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29", "r74", "r141", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r263", "r264", "r265", "r278", "r317", "r318", "r319" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Salaries and Payroll Taxes Related Parties and Other" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Commitment fee", "verboseLabel": "Commitment fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Conversion percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "[Loans Payable, Current]", "verboseLabel": "Loan payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 23.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r54", "r58", "r61" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r37", "r38", "r41", "r44", "r61", "r74", "r81", "r83", "r84", "r86", "r87", "r91", "r92", "r98", "r120", "r122", "r125", "r128", "r130", "r141", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r276", "r278", "r375", "r386" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Option issued" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases (Details)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r24", "r76", "r312" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Convertible note payable - related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r76", "r311", "r385" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Related party payables" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r120", "r122", "r125", "r128", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Net loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r301", "r307" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost (included in general and administrative in the Company's consolidated statement of operations)", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails", "http://ipharminc.com/role/OperatingLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Impairment expense of operating lease" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r299" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "[Operating Lease, Liability]", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails1", "http://ipharminc.com/role/OperatingLeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r299" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://ipharminc.com/role/OperatingLeasesDetails1": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease - current liability", "verboseLabel": "Short-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/OperatingLeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r299" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails1": { "order": 3.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease - long term liability", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/OperatingLeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r300", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for amounts included in the measurement of lease liabilities for the six months ended December 31, 2021" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operatng lease, right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of the right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r304", "r307" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fiscal Year Ending June 30," } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r171", "r293", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "8. Operating Leases" } } }, "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_OptionIndexedToIssuersEquityIndexedShares": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The number of issuer's shares to which the option contract is indexed.", "label": "Equity incentive shares" } } }, "localname": "OptionIndexedToIssuersEquityIndexedShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r206", "r270" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Exercise price" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Nature of Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r10", "r370", "r379" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "[Other Assets]", "totalLabel": "Total Other Assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets:" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r234", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative", "http://ipharminc.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative", "http://ipharminc.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r207" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares designated" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r207" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value, 10,000,000 designated shares, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r21", "r22" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r51" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from issuance of preferred stocks and warrants, net of financing costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Issuance of Series B-2 preferred stock at fair value" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/FairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r50" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Sale of common stock, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Loan proceeds" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/LoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Note payable to officer" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfTreasuryStock": { "auth_ref": [ "r50" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.", "label": "[Proceeds from Sale of Treasury Stock]", "negatedLabel": "Purchase of treasury stock" } } }, "localname": "ProceedsFromSaleOfTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r50", "r250" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of options", "verboseLabel": "Proceeds from stock option exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r50" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of preferred stock warrants", "verboseLabel": "Proceeds from exercise price" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r402", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases (Details Narrative)" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r230", "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r230", "r310", "r311", "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction Axis" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/LiquidityDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r230", "r310", "r314", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r308", "r309", "r311", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "10. Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Debt repayment" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r52" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Repayment of note payable to officer" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exclusive License Agreement" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r257", "r354", "r407" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockAwardForfeituresDividends": { "auth_ref": [ "r222", "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of dividends forfeited related to restricted stock awards forfeited.", "label": "Stock awards" } } }, "localname": "RestrictedStockAwardForfeituresDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable Related Party" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r224", "r254", "r319", "r382", "r394", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r78", "r79", "r80", "r82", "r89", "r92", "r142", "r251", "r252", "r253", "r258", "r259", "r274", "r390", "r392" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r43", "r74", "r117", "r118", "r121", "r126", "r127", "r131", "r132", "r133", "r141", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r278", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of aggregate shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/AccruedExpensesRelatedPartiesAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Components of stock-based compensation expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of basic and diluted earning per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r156", "r159" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of patents" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/PatentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of operating lease liabilities" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRentExpenseTableTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.", "label": "Schedule of components of lease expense" } } }, "localname": "ScheduleOfRentExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Schedule of vesting outstanding restricted stock" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Restricted Stock Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in stock options.", "label": "Schedule of stock option activity" } } }, "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r34" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_OtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation", "verboseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Total shares forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Total shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r237", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Awards outstanding, Ending balance", "periodStartLabel": "Beginning balance, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price]", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Accounting for Stock Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "[Share Price]", "verboseLabel": "Exercise price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r243", "r255" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life, beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "[Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price]", "periodStartLabel": "Weighted average, Beginning balance" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance shares", "periodStartLabel": "Balance shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "12. Loan payable" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/LoanPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67", "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "3. Significant Accounting Policies and Recent Accounting Pronouncements" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r71", "r74", "r95", "r96", "r97", "r99", "r101", "r106", "r107", "r108", "r141", "r172", "r176", "r177", "r178", "r181", "r182", "r207", "r208", "r211", "r215", "r222", "r278", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock Axis" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/FairValueMeasurementDetails", "http://ipharminc.com/role/LiquidityDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative", "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r32", "r39", "r40", "r41", "r78", "r79", "r80", "r82", "r89", "r92", "r105", "r142", "r222", "r224", "r251", "r252", "r253", "r258", "r259", "r274", "r281", "r282", "r283", "r284", "r285", "r286", "r390", "r391", "r392", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components Axis" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative", "http://ipharminc.com/role/FairValueMeasurementDetails", "http://ipharminc.com/role/LiquidityDetailsNarrative", "http://ipharminc.com/role/LoanPayableDetailsNarrative", "http://ipharminc.com/role/PatentsNetDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative", "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r78", "r79", "r80", "r105", "r355" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails1", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails3", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails4", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative", "http://ipharminc.com/role/ExclusiveLicenseAgreementDetailsNarrative", "http://ipharminc.com/role/FairValueMeasurementDetails", "http://ipharminc.com/role/LiquidityDetailsNarrative", "http://ipharminc.com/role/LoanPayableDetailsNarrative", "http://ipharminc.com/role/PatentsNetDetails", "http://ipharminc.com/role/PatentsNetDetailsNarrative", "http://ipharminc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative", "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock issued, shares", "verboseLabel": "Common shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r14", "r15", "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock options reserved for future issuance" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r222", "r224", "r239" ], "calculation": { "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails": { "order": 2.0, "parentTag": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock options", "verboseLabel": "Stock option exercise, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock issued, value" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r32", "r222", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Option exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Stock Option [Member]", "verboseLabel": "Stock Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock option expenses" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockTransactionsParentheticalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Transactions" } } }, "localname": "StockTransactionsParentheticalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r74", "r135", "r141", "r278", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total Stockholders' Equity", "periodEndLabel": "Balance amount", "periodStartLabel": "Balance amount" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets", "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r72", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r224", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "14. Equity Transactions" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r287", "r321" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r287", "r321" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r287", "r321" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r320", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "16. Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "2. Liquidity" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r197", "r220", "r272", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r411", "r412", "r413", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails", "http://ipharminc.com/role/EquityIncentivePlansStockbasedCompensationExerciseOfOptionsAndWarrantsOutstandingDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/EquityTransactionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r31", "r225" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r31", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock Shares", "terseLabel": "Treasury Stock Shares", "verboseLabel": "Treasury Stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://ipharminc.com/role/ConvertibleNotePayableRelatedPartyDetailsNarrative", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r31", "r225", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "[Treasury Stock, Value]", "negatedLabel": "Treasury Stock, at cost (10,874,593 shares as of December 31, 2021 and June 30, 2021)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r109", "r110", "r111", "r112", "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r302", "r307" ], "calculation": { "http://ipharminc.com/role/OperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/OperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and diluted weighted average number of common shares", "verboseLabel": "Total weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r94" ], "calculation": { "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails": { "order": 4.0, "parentTag": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Restricted stock grants" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ipharminc.com/role/SignificantAccountingPoliciesAndRecentAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r408": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r409": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r410": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r411": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r412": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r413": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r415": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r416": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r417": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r418": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" } }, "version": "2.1" }